Status:
ACTIVE_NOT_RECRUITING
Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly
Lead Sponsor:
Cedars-Sinai Medical Center
Conditions:
Acromegaly
Eligibility:
All Genders
18-90 years
Brief Summary
Acromegaly is a rare disorder characterized by excessive production of growth hormone most often by a pituitary adenoma. A pituitary adenoma is a tumor, almost always benign or non-cancerous, that gro...
Detailed Description
Acromegaly Overview Acromegaly is a rare, insidious disorder characterized by excessive secretion of growth hormone (GH) almost always from a pituitary adenoma. (Melmed NEJM 1990) Excess GH secretion...
Eligibility Criteria
Inclusion
- Male or Female age 18-90
- Diagnosed with acromegaly from a pituitary adenoma visualized by MRI, and with elevated IGF-1 levels compared to age and gender matched control values and nadir GH response to OGTT\>1mg/L
- Having already agreed to undergo surgical resection of their pituitary adenoma prior to study entry
- Must provide informed consent
Exclusion
- Inability to complete the protocol due to intercurrent medical or psychiatric illness
- Pregnant or breastfeeding
- Use of insulin
- Use of estrogen, progesterone, testosterone or thyroid hormone will be allowed as long as the dose is stable during the study
Key Trial Info
Start Date :
June 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00921609
Start Date
June 1 2006
End Date
April 1 2025
Last Update
April 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cedars-Sinai Medical Center, Pituitary Center
Los Angeles, California, United States, 90048